Hepatitis A and E, an infection of the liver, can last for four-five weeks.

Hepatitis virus has five commonly known strains: Type A, B, C, D. All of them affect the liver but there are some key differences in origin...

The move is expected to slash prices of some of these drugs, like Hepatitis B immunoglobulin, by as much as 20%, a senior government told E...

Scientists at the Institute of Microbial Technology (IMTECH), Chandigarh, have for the first time in India developed indigenous technology ...

And that's just one leukaemia drug. India's generic industry has been producing many such life-saving medicines at a fraction of the global...

Typically, the price of many expensive patented drugs in European countries like France, Spain or the UK is half of what these cost in the ...

If scaling up of HIV treatment globally was made possible by Indian generics companies, it looks like they are set to repeat this feat with...

Last year, Strides had entered into a licensing agreement with Gilead Sciences to bring Hepatitis C cure to 91 developing countries.

Hetero is the first company in India to receive the approval for the fixed-dose combination Ledipasvir-Sofosbuvir (90mg/400mg) from DCGI.

India is now one of the few countries where generics are available for interferon-free treatment of Hepatitis C.

The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health im...

Strides Arcolab today announced launch of the generic version of Hepatitis C drug 'Sofosbuvir' under the brand name 'Virso'.

The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries, Cipla said.

The vaccination aims to reduce the number of chronic carriers who could infect others and themselves develop liver cancers or cirrhosis lat...

The voluntary licencing deal promises to make the drug cheap in India as well as up to 91 countries where the Indian firms are allowed to s...

The findings can bring an effective hepatitis C vaccine closer to reality.

The drug maker's subsidiary MSD India currently has about 700 employees, which we will increase to 1,000 by December, 2009. Job-hopping: Pr...